The material news: the March 9, 2026 Hims & Hers-Novo Nordisk partnership gives Hers patients legitimately branded oral Wegovy at $149/mo (intro through August 31, 2026, rising to $199 after)
Conversely, a single-institution study of 1,191 participants failed to find a difference in the rate of new retinopathy or existing retinopathy progression between GLP-1/GIP agonist or SGLT2 inhibitors when the amount of hemoglobin A1c reduction was the same in the two treatment arms
FDA warnings and enforcement actions The FDA has significantly increased scrutiny of compounded GLP-1 medications
Lost over 60 lbs *Personal results may vary based on our individualized health programs
The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
Expanding our knowledge of the metabolic pathways involved in ICP regulation and IIH maybe an important step for future research, which could lead to the identification of novel targeted therapies for patients with IIH